Drug
Bimagrumab
Bimagrumab: highest development phase Phase 2, developed by Eli Lilly, Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly, Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bimagrumab NCT07920887 | Phase 2 | Heart Failure, Diastolic |
| bimagrumab NCT02333331 | Phase 2 | Sarcopenia |
Latest
No recent events.
Follow Bimagrumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.